Abstract
In 12 patients with relapsed or refractory acute myelogenous leukemia (AML), the efficacy and safety of a novel regimen, namely thalidomide combined with interferon and interleukin 2 (IL-2), were initially explored.All the patients have received the triple-drug regimen for at least one cycle.Three patients achieved incomplete remission (CRi), 3 patients with partial remission.The overall response rate (ORR) was 50%.
MeSH terms
-
Adult
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Female
-
Humans
-
Interferons / administration & dosage
-
Interferons / therapeutic use*
-
Interleukin-2 / administration & dosage
-
Interleukin-2 / therapeutic use*
-
Leukemia, Myeloid, Acute / drug therapy*
-
Male
-
Middle Aged
-
Recurrence
-
Remission Induction
-
Thalidomide / administration & dosage
-
Thalidomide / therapeutic use*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Interleukin-2
-
Thalidomide
-
Interferons